• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Inari Medical Inc.

    2/19/25 9:04:49 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care
    Get the next $NARI alert in real time by email
    S-8 POS 1 d903746ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on February 19, 2025

    Registration No. 333-238735

    Registration No. 333-254133

    Registration No. 333-262931

    Registration No. 333-270056

    Registration No. 333-277497

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-238735

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-254133

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-262931

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270056

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-277497

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    INARI MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2902923

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    6001 Oak Canyon, Suite 100

    Irvine, California 92618

    (Address of Principal Executive Offices) (Zip Code)

     

     

    2011 EQUITY INCENTIVE PLAN

    2020 INCENTIVE AWARD PLAN

    AMENDED AND RESTATED 2020 EMPLOYEE STOCK PURCHASE PLAN (F/K/A THE 2020

    EMPLOYEE STOCK PURCHASE PLAN)

    (Full titles of the plans)

    Robert S. Fletcher

    Stryker Corporation

    1941 Stryker Way

    Portage, Michigan 49002

    (269) 385-2600

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Seth H. Katz

    Scott R. Williams

    Sally Wagner Partin

    Sidley Austin LLP

    One South Dearborn

    Chicago, Illinois 60603

    (312) 853-7000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    These post-effective amendments (the “Post-Effective Amendments”), filed by Inari Medical, Inc., a Delaware corporation (the “Company”), remove from registration all shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) previously registered under the following Registration Statements on Form S-8 filed by the Company (the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “SEC”) pertaining to the registration of shares of Common Stock.

     

      •  

    Registration No. 333-238735, which was previously filed with the SEC on May 27, 2020, registering 4,239,862 shares of Common Stock under the 2011 Equity Incentive Plan, 990,870 shares of Common Stock under the 2020 Employee Stock Purchase Plan, and 3,737,313 shares of Common Stock under the 2020 Incentive Award Plan;

     

      •  

    Registration No. 333-254133, which was previously filed with the SEC on March 11, 2021, registering 1,477,548 shares of Common Stock under the 2020 Incentive Award Plan and 492,516 shares of Common Stock under the 2020 Employee Stock Purchase Plan;

     

      •  

    Registration No. 333-262931, which was previously filed with the SEC on February 23, 2022, registering 1,509,404 shares of Common Stock under the 2020 Incentive Award Plan and 503,135 shares of Common Stock under the Amended and Restated 2020 Employee Stock Purchase Plan;

     

      •  

    Registration No. 333-270056, which was previously filed with the SEC on February 27, 2023, registering 1,620,650 shares of Common Stock under the 2020 Incentive Award Plan and 540,217 shares of Common Stock under the Amended and Restated 2020 Employee Stock Purchase Plan; and

     

      •  

    Registration No. 333-277497, which was previously filed with the SEC on February 29, 2024, registering 1,732,872 shares of Common Stock under the 2020 Incentive Award Plan and 577,624 shares of Common Stock under the Amended and Restated 2020 Employee Stock Purchase Plan.

    On January 6, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Stryker Corporation, a Delaware corporation (“Parent”), and, by way of a joinder dated January 7, 2025, Eagle 1 Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Offeror”). On February 19, 2025, pursuant to the Merger Agreement, Offeror merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”).

    As a result of the Merger, the Company has terminated all offerings of the Company’s securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all plan interests and any and all securities registered for issuance under the Registration Statements that remain unsold as of the date hereof. This filing is made in accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance that remain unsold at the termination of the offering.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on this February 19, 2025.

     

    INARI MEDICAL, INC.
     By:  

    /s/ Andrew Hykes

      Name: Andrew Hykes
      Title: Chief Executive Officer and President

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $NARI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NARI

    DatePrice TargetRatingAnalyst
    12/17/2024$75.00Outperform
    Oppenheimer
    9/18/2024$50.00Hold
    Stifel
    9/3/2024$47.00Market Perform
    Leerink Partners
    8/9/2024$68.00Buy
    Deutsche Bank
    7/25/2024Outperform
    William Blair
    7/18/2024Buy → Hold
    Needham
    2/29/2024$85.00 → $55.00Overweight → Neutral
    Piper Sandler
    1/23/2024$72.00Buy
    Needham
    More analyst ratings

    $NARI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Milder Donald B bought $2,998,063 worth of shares (56,100 units at $53.44) (SEC Form 4) (Amendment)

    4/A - Inari Medical, Inc. (0001531048) (Issuer)

    5/31/24 4:54:38 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Milder Donald B bought $2,998,063 worth of shares (56,100 units at $53.44) (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    11/8/23 5:48:54 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Warner Robert Keith closing all direct ownership in the company (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    2/19/25 8:26:35 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Tu Thomas was granted 7,406 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    2/19/25 8:22:46 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Director Szyman Catherine M. closing all direct ownership in the company (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    2/19/25 8:20:54 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    SEC Filings

    View All

    SEC Form 15-12G filed by Inari Medical Inc.

    15-12G - Inari Medical, Inc. (0001531048) (Filer)

    3/3/25 6:06:19 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    SEC Form 25-NSE filed by Inari Medical Inc.

    25-NSE - Inari Medical, Inc. (0001531048) (Subject)

    2/19/25 9:11:12 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Inari Medical Inc.

    S-8 POS - Inari Medical, Inc. (0001531048) (Filer)

    2/19/25 9:07:02 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Inari with a new price target

    Oppenheimer initiated coverage of Inari with a rating of Outperform and set a new price target of $75.00

    12/17/24 7:53:14 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Inari with a new price target

    Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00

    9/18/24 7:45:45 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Leerink Partners initiated coverage on Inari with a new price target

    Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00

    9/3/24 8:10:13 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Leadership Updates

    Live Leadership Updates

    View All

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $NARI
    Financials

    Live finance-specific insights

    View All

    Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

    Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

    2/19/25 8:30:00 AM ET
    $NARI
    $SYK
    Medical/Dental Instruments
    Health Care

    Inari Medical Reports Third Quarter 2024 Financial Results

    IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t

    10/28/24 4:05:00 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Inari Medical to Announce Third Quarter 2024 Financial Results

    IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc

    10/7/24 4:05:00 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

    11/8/24 2:17:22 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

    11/8/24 10:29:30 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

    11/7/24 4:49:55 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

    Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

    2/19/25 8:30:00 AM ET
    $NARI
    $SYK
    Medical/Dental Instruments
    Health Care

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments